BIONTECH SE

BioNTech SE reports Phase‑3 success for trastuzumab pamirtecan, boosting PFS in HR⁺/HER2‑low breast cancer, and Phase‑2 data for pumitamig show a 36.7% ORR in advanced NSCLC.

BioNTech’s latest mRNA cancer trial fails to hit PFS targets, but the company’s robust cash reserve and long‑term pipeline keep investors watching for future breakthroughs.